After an advanced trial of Ultragenyx Pharma's advanced bone disease drug failed, the stock price plummeted 43%.

Zhitongcaijing · 1d ago
After an advanced trial of Ultragenyx Pharma's advanced bone disease drug failed, the stock price plummeted 43%.